Clinical homologous recombination repair gene reversion analysis identifies mechanisms of resistance to PARP inhibitors and platinum‐chemotherapy

Abstract Identifying mechanisms underlying cancer resistance to therapy is vital for advancing treatment strategies. Pathogenic mutations of homologous recombination repair (HRR) genes are known biomarkers for platinum (Pt)‐based chemotherapy and poly ADP ribose polymerase inhibitors (PARPi) effecti...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yan Jia, Qiong Yang, Yutong Ma, Miaofang Wu, Qiuxiang Ou, Zhongqiu Lin, Yunyu Wu, Jing Li
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2024-06-01
Col·lecció:	MedComm – Oncology
Matèries:	drug resistance homologous recombination repair PARP inhibitor platinum‐chemotherapy reversion mutation
Accés en línia:	https://doi.org/10.1002/mog2.79
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!